Are you Toshimitsu Kobayashi?

Claim your profile

Publications (4)7.52 Total impact

  • Momokazu Gotoh, Toshimitsu Kobayashi, Keizo Sogabe
    [Show abstract] [Hide abstract]
    ABSTRACT: AimsTo analyze the impact of overactive bladder (OAB) symptoms and patient characteristics on symptom bother and quality of life (QOL).Methods An analysis of the data of 967 patients from SET-Q, a prospective, multicenter, open, observational study in the post-marketing setting, was performed. The eligible subjects were treatment-naive female patients with OAB who complained of an urgency episode at least once a week. Symptom bother and QOL were assessed by the OAB-questionnaire (OAB-q), and severity of OAB symptoms was estimated by the OAB symptom score (OABSS). Multiple regression analysis was utilized for clarifying how OAB symptom severity affects QOL.ResultsThe symptoms with the highest bother score were daytime frequency and urgency in the under-50s age group, urgency in the 50s, 60s, and 70s age groups, night-time frequency and urgency incontinence in the over-80s age group, respectively. With an increase in severity of OAB as well as severity of urgency assessed by the OABSS, an increase in symptom bother and impairment in health-related quality of life (HRQL) in the OAB-q were observed. Multiple regression analysis demonstrated the significant relationship with urgency and nighttime frequency to symptom bother, and also significant interaction between age and urgency incontinence, associated with further negative effect on HRQLs in elderly patients.Conclusions This large sample study, by utilizing the scored questionnaire for symptom severity, bother and HRQL, showed that the symptoms with the highest bother were age-dependent. It was also confirmed that symptom bother will be inferred by the OABSS. Neurourol. Urodynam. © 2014 Wiley Periodicals, Inc.
    Neurourology and Urodynamics 09/2014; · 2.67 Impact Factor
  • Momokazu Gotoh, Toshimitsu Kobayashi, Keizo Sogabe
    [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the relationship between symptom improvement and health-related quality of life in female overactive bladder patients treated with solifenacin. We carried out a prospective, multicenter, open-label study. Eligible patients were treatment-naive female patients with overactive bladder, with an urgency episode at least once a week. Symptoms were quantitatively assessed by the Overactive Bladder Symptom Score, and quality of life by the Overactive Bladder questionnaire. Changes of symptom severity, bother, and quality of life were assessed at baseline and 12 weeks after treatment with solifenacin 5, 7.5 or 10 mg once daily. Data from 523 patients (mean age 66 years) were analyzed. Solifenacin significantly improved the total Overactive Bladder Symptom Score and also all subscores for the four symptoms (daytime frequency, urgency, night-time frequency and urgency incontinence). Solifenacin also significantly improved the four quality of life subscales, total quality of life and symptom bother scores of the Overactive Bladder questionnaire. The severity of night-time frequency at baseline positively affected the improvement in the quality of life subscale of Sleep, and the severity of daytime frequency at baseline positively affected the improvement of coping and social interaction. Improvement of severity in various symptoms positively affected the improvement of bother and the quality of life subscales. Solifenacin provides an overall improvement of bother and quality of life in female overactive bladder patients. Symptom severity before treatment and improvement of symptom severity seem to variably affect this improvement.
    International Journal of Urology 12/2013; · 1.73 Impact Factor
  • Source
    Journal of Infection and Chemotherapy 07/2011; · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The safety and efficacy of micafungin were evaluated in a Japanese post-marketing survey involving 1,142 patients with deep mycosis caused by Candida or Aspergillus. The overall clinical response was 83.0%, and the respective responses for patients with candidiasis or aspergillosis were 86.3 and 70.8%. With regard to drug reactions, 562 adverse reactions were observed in 28.5% of patients. Among the 83 serious adverse drug reactions reported by 53 patients, a causal relationship with micafungin was assessed as definite or probable for 6 reactions in 5 patients. Age and baseline hepatic and renal function status did not affect the incidence of adverse reactions, although incidence increased significantly in proportion to the severity of mycosis and daily dose (p < 0.01). In multiple logistic regression analysis, neither baseline hepatic impairment nor increased daily dose of micafungin affected the incidence of hepatobiliary disorders, however, the severity of mycosis was found to correlate significantly with hepatobiliary disorders (p = 0.031). Taken together, our post-marketing findings show that micafungin is effective against deep mycosis caused by Candida or Aspergillus in patients across a range of backgrounds.
    Journal of Infection and Chemotherapy 03/2011; 17(5):622-32. · 1.55 Impact Factor